Page 210 - Genentech News Today

This new test for researchers specifically targets the XBB.1.5 Omicron sub-variant and runs on the real-time PCR platforms LightCycler® 480 II* and cobas® z480.Results from the test will help closely track

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

Over the last few years, physicians have experimented with taking patients with chronic myeloid leukemia (CML) off their drugs entirely, and the results are promising.

/PRNewswire/ -- Do you have hives that do not go away? If your itchy bumps and painful welts last 6 weeks or longer, this is known as chronic urticaria, or...

On January 6, 2023, Genentech and Tanvex reached a settlement in principle to resolve all claims with respect to Genentech's BCPIA complaint.

Advisers will vote on whether to recommend replacing the primary Covid-19 vaccine series with the updated bivalent boosters available from Pfizer-BioNTech and Moderna.

Negative trade secrets protect a company’s secret know-how gained from extensive research investment about what does not work.

Liposomal irinotecan plus chemo in the new NALIRIFOX regimen significantly improved overall survival compared with standard therapy in metastatic pancreatic ductal adenocarcinoma.

2022 heralded the next chapter for biosimilars in the United States, including U.S. Food and Drug Administration approval of biosimilars in new therapeutic areas, additional...

“She’s still with us, she’s thriving wonderfully. There is hope. You just have to find the right people, the right doctors, the right support system